No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BLUE bluebird bio
- 0.908
- +0.013+1.41%
Trading May 31 09:30 ET
175.05MMarket Cap-1441P/E (TTM)
0.909High0.900Low51.34KVolume0.900Open0.896Pre Close46.28KTurnover0.03%Turnover RatioLossP/E (Static)192.74MShares5.53052wk High0.79P/B174.27MFloat Cap0.85152wk Low--Dividend TTM191.88MShs Float152.883Historical High--Div YieldTTM1.04%Amplitude0.851Historical Low0.901Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
No Data
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
Bluebird Bio Announces CFO Transition and Compensation Details
Bluebird Bio Says Continuing To Work Expeditiously To Complete Delayed Filings
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a resu
Express News | Bluebird bio Inc - Appointed Chief Financial Officer (CFO), Effective June 10, 2024
Express News | Bluebird bio Appoints O. James Sterling as Chief Financial Officer
Bluebird Bio Appoints O. James Sterling As Chief Financial Officer >BLUE
Bluebird Bio Appoints O. James Sterling As Chief Financial Officer >BLUE
Comments
$bluebird bio(BLUE.US$ Seems i have majority of posts in this thread since beginning of year! Hehehe! But im going to give one more! IMO from the latest update and from the earnings call! ( Which I recommend you read the earnings call transcript ) I see earnings from this company just getting better and better! IMO im looking for it to just keep growing going forward! And if you read the transcript? Im sure you to will see why i say this. Happy reading![]()
4
2
$bluebird bio(BLUE.US$ Reuters· 1 min ago
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
Bluebird bio Inc - Anticipates Recognizing Revenue From Its First Infusion of Lyfgenia in Q3 of 2024
1
$bluebird bio(BLUE.US$ Bluebird bio Announces Completion of First Cell Collection for Lyfgenia™ Gene Therapy
$bluebird bio(BLUE.US$ Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across HHS Leaves Little Doubt That The New Therapy Will Qualify"
4
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
MARKET-TEST-DUMMY : Seems like more time is needed but heading on the right path to getting patients in line. They seem optimistic as far as the company goes. I'm sure there's a lot of bureaucracy and red tape to getting payments. Like anything else, it should get easier as they go or as they set precedent, so it seems. Not all QTC's are equal and interesting some don't want to be listed on their website though. Wonder if that's a product thing or just not in need of an another patient. Either way, appreciate ya pointing this out. Will be keeping eye on this one too.
TrytosaveabitOP MARKET-TEST-DUMMY: You’re very welcome! Where ya been. I was thinking wow his work musta really picked up. Well at least I’m hoping it was that and nothings gone bad! Anyways good to see ya